title: Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
authors: Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors: Arun A
authors: AA
authors: Azad
authors: Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: kchi@bccancer.bc.ca.
authors: Kim N
authors: KN
authors: Chi
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D065607:Cytochrome P-450 Enzyme Inhibitors / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D065088:Steroid Synthesis Inhibitors / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D065607:Cytochrome P-450 Enzyme Inhibitors; D065088:Steroid Synthesis Inhibitors; D000069501:Abiraterone Acetate